Biotest AG / DE0005227235
15.11.2024 - 09:00:06Minister of Economic Affairs Mansoori and Lord Mayor Benz visit Biotest's plasma center in Darmstadt and call for plasma donations
| Biotest AG / Key word(s): Miscellaneous 15.11.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Plasma donation centers in Europe to secure the long-term supply of plasma Dreieich, Germany, November 15, 2024. Darmstadt's most modern blood plasma donation center in the TOWN HOUSE in the former Roemer department store at the White Tower (Weisser Turm) had prominent visitors. On November 14, numerous guests from politics and business took the opportunity to visit the state-of-the-art plasma donation center at Ernst-Ludwig-Strasse 12. Among the guests were Kaweh Mansoori, Hessian Minister of Economics and Deputy Prime Minister, Hanno Benz, Lord Mayor of Darmstadt, and Peter Franz and Bijan Kaffenberger, Members of the State Parliament. The center is operated by Plasma Service Europe GmbH, a wholly-owned subsidiary of Biotest AG, which was founded more than 20 years ago to strengthen plasma donation in Germany. Hesse's Minister of Economics, Kaweh Mansoori, emphasizes: "The Darmstadt Plasma Center opposite the White Tower, is not only an important step in providing patients with life-saving medications. It also creates qualified jobs and revitalizes the city center in a prominent location. Both the people from the region who respond to the call to donate plasma and the employees make an important contribution to the care of seriously ill patients". Lord Mayor Hanno Benz sees the new plasma center as an opportunity to raise public awareness of blood plasma donation. "Blood donation is well known, plasma donation less so. However, plasma is also a vital component of medical treatment, especially in the care of people with serious illnesses. It is important to emphasize the importance of plasma donation in our society and to encourage more people to donate regularly. Every donation can save a life, and together we can significantly improve patient care". In addition to Peter Janssen, CEO of Biotest AG, and the management of Plasma Service Europe GmbH, a number of interesting guests were also present. Among them was Dr Gerd Klock, patient representative of dsai e.V., a patient organization for congenital immunodeficiencies. He shared his moving life story and spoke to the interested guests about the vital importance of plasma donation for him. Plasma Service Europe GmbH has an important supply mission: plasma serves as the basis for various, often vital medications. Many rare diseases are treated with medicines made from blood plasma. Since blood plasma cannot be produced artificially, plasma donations are vital for many people. Peter Janssen, CEO of Biotest AG, welcomed the attendees and highlighted the advantages of the centrally located site: "The state-of-the-art equipment of the Plasma Service center ensures a pleasant atmosphere in which donors feel comfortable. The motivated and highly qualified team enables convenient and smooth donations under professional medical supervision, five days a week, from Monday to Friday. We also hope to welcome many employees of Biotest AG here in Darmstadt." The collected plasma is processed exclusively in Germany at Biotest AG in Dreieich. Regular audits in Germany ensure that the high legal and internal quality and safety requirements are met. About human blood plasma Human blood plasma is the source material for the production of plasma protein preparations used in the treatment of various diseases of the immune system and the blood system as well as in emergency medicine. Biotest is one of the six largest manufacturers of plasma protein products in the world. About Plasma Service Europe Plasma Service Europe GmbH is a wholly owned-subsidiary of Biotest AG, which was founded in 2001 and today operates 14 of the most modern plasmapheresis centers in Germany. Its core competence lies in the collection of blood plasma. To date, more than 170,000 donors have been welcomed. The goal for the future is to be able to supply even more patients with vital medicines. About Biotest Biotest (www.biotest.com) is a provider of biological therapeutics derived from human plasma. With a value-added chain that extends from preclinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of clinical immunology, hematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. Biotest has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German Stock Exchange. Since May 2022, Biotest has been a part of the Grifols Group, headquartered in Barcelona, Spain (www.grifols.com). IR contact Dr Monika Baumann (Buttkereit) Phone: +49-6103-801-4406 Mail: ir@biotest.com PR contact Dirk Neumüller Phone: +49-6103-801-269 Mail: pr@biotest.com Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Preference shares: securities’ ID No. 522723; ISIN DE0005227235 Listing: Frankfurt (Prime Standard) Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. 15.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
| Language: | English |
| Company: | Biotest AG |
| Landsteinerstraße 5 | |
| 63303 Dreieich | |
| Germany | |
| Phone: | 0 61 03 - 8 01-0 |
| Fax: | 0 61 03 - 8 01-767 |
| E-mail: | ir@biotest.com |
| Internet: | www.biotest.com |
| ISIN: | DE0005227235, DE0005227201 |
| WKN: | 522723, 522720 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2030621 |
| End of News | EQS News Service |
| |
